ZBH - Zimmer Biomet Holdings Inc Stock Price, Fair Value and News

121.14USD+0.36 (+0.30%)Delayed as of 23 Apr 2024, 03:30 pm ET

Market Summary

USD121.14+0.36

Delayedas of 23 Apr 2024, 03:30 pm

0.30%

ZBH Stock Price

View Fullscreen

ZBH RSI Chart

ZBH Valuation

Market Cap

24.8B

Price/Earnings (Trailing)

24.19

Price/Sales (Trailing)

3.35

EV/EBITDA

16.07

Price/Free Cashflow

19.19

ZBH Price/Sales (Trailing)

ZBH Profitability

EBT Margin

14.43%

Return on Equity

8.2%

Return on Assets

4.76%

Free Cashflow Yield

5.21%

ZBH Fundamentals

ZBH Revenue

Revenue (TTM)

7.4B

Rev. Growth (Yr)

6.3%

Rev. Growth (Qtr)

10.63%

ZBH Earnings

Earnings (TTM)

1.0B

Earnings Growth (Yr)

421.23%

Earnings Growth (Qtr)

157.65%

Breaking Down ZBH Revenue

52 Week Range

108.20149.25

(Low)(High)

Last 7 days

-2.6%

Last 30 days

-5.1%

Last 90 days

-0.3%

Trailing 12 Months

-12.4%

How does ZBH drawdown profile look like?

ZBH Financial Health

Current Ratio

1.61

Debt/Equity

0.39

Debt/Cashflow

0.32

ZBH Investor Care

Dividend Yield

0.79%

Dividend/Share (TTM)

0.96

Buy Backs (1Y)

1.86%

Diluted EPS (TTM)

4.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.1B	7.2B	7.3B	7.4B
2022	6.9B	6.9B	6.9B	6.9B
2021	6.8B	7.4B	7.1B	6.8B
2020	7.8B	7.0B	7.1B	7.0B
2019	7.9B	7.9B	7.9B	8.0B
2018	7.8B	7.9B	7.9B	7.9B
2017	7.8B	7.8B	7.7B	7.8B
2016	6.8B	7.5B	7.6B	7.7B
2015	4.6B	4.6B	5.3B	6.0B
2014	4.6B	4.7B	4.7B	4.7B
2013	4.5B	4.5B	4.6B	4.6B
2012	4.5B	4.5B	4.5B	4.5B
2011	4.3B	4.4B	4.4B	4.5B
2010	4.2B	4.2B	4.2B	4.2B
2009	4.1B	4.0B	4.0B	4.1B
2008	0	4.0B	4.0B	4.1B
2007	0	0	0	3.9B

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zimmer Biomet Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	winkler lori	acquired	-	-	772	svp and chro
Apr 01, 2024	winkler lori	sold (taxes)	-28,089	130	-215	svp and chro
Mar 07, 2024	yi sang	sold	-216,296	126	-1,705	group president, asia pacific
Mar 07, 2024	yi sang	acquired	156,059	91.53	1,705	group president, asia pacific
Mar 06, 2024	ellingson rachel	sold (taxes)	-55,989	125	-445	svp & chief strategy officer
Mar 06, 2024	upadhyay suketu	sold (taxes)	-241,449	125	-1,919	exec. vp, cfo
Mar 06, 2024	upadhyay suketu	acquired	-	-	4,561	exec. vp, cfo
Mar 06, 2024	phipps chad f	sold (taxes)	-103,802	125	-825	sr. vp/gen counsel/secretary
Mar 06, 2024	yi sang	acquired	-	-	2,365	group president, asia pacific
Mar 06, 2024	stellato paul a	acquired	-	-	609	vp, controller & cao

Which funds bought or sold ZBH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	185	2,376	-%
Apr 19, 2024	TRUST POINT INC.	reduced	-42.31	-203,199	339,585	0.03%
Apr 19, 2024	Olstein Capital Management, L.P.	reduced	-2.45	470,000	8,579,000	1.40%
Apr 19, 2024	Covea Finance	added	7.33	2,858,910	20,298,500	0.96%
Apr 19, 2024	Tradewinds Capital Management, LLC	unchanged	-	1,072	13,459	-%
Apr 19, 2024	Uncommon Cents Investing LLC	reduced	-0.28	216,017	2,868,650	0.88%
Apr 19, 2024	First Trust Direct Indexing L.P.	added	2.51	99,730	992,886	0.07%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	added	0.15	5,190,450	65,461,200	0.04%
Apr 19, 2024	Leeward Investments, LLC - MA	added	3.99	1,647,200	14,542,000	0.64%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	unchanged	-	2,000	20,000	-%

Are Funds Buying or Selling ZBH?

Are funds buying ZBH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZBH

No. of Funds

Unveiling Zimmer Biomet Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	4.5%	9,426,866	SC 13G
Feb 13, 2024	dodge & cox	5.5%	11,474,535	SC 13G
Feb 13, 2024	vanguard group inc	11.42%	23,858,865	SC 13G/A
Jan 25, 2024	blackrock inc.	9.0%	18,704,377	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	5.3%	11,200,109	SC 13G
Feb 09, 2023	vanguard group inc	11.46%	24,055,739	SC 13G/A
Jan 30, 2023	blackrock inc.	10.4%	21,803,709	SC 13G/A
Jan 24, 2023	blackrock inc.	10.4%	21,803,709	SC 13G/A
Nov 07, 2022	jpmorgan chase & co	2.4%	5,091,869	SC 13G/A
Apr 08, 2022	vanguard group inc	11.04%	23,102,761	SC 13G/A

Recent SEC filings of Zimmer Biomet Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Zimmer Biomet Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.8B	40.1B	-3.17%	-4.12%	32.46	4.63	-8.12%	-17.45%
BDX	67.6B	19.5B	-4.91%	-10.36%	53.86	3.47	4.02%	-22.04%
ALGN	22.6B	3.9B	-5.82%	-15.30%	50.76	5.85	3.42%	23.09%
BAX	20.5B	14.8B	-3.67%	-10.80%	7.72	1.39	2.12%	209.17%
MID-CAP
ATR	9.3B	3.5B	-0.90%	16.36%	32.56	2.66	4.97%	18.89%
HSIC	9.3B	12.3B	-1.49%	-14.91%	22.25	0.75	-2.44%	-22.68%
BIO	8.2B	2.7B	-20.12%	-40.09%	-12.83	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.30%	-26.11%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-2.14%	10.95%	-561.72	9.3	33.86%	89.83%
PDCO	2.3B	6.6B	-4.88%	-5.43%	11.99	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.12%	-21.63%	-1.88	0.4	7.73%	-1066.14%
ANIK	385.4M	166.7M	2.04%	-4.03%	-4.66	2.31	6.67%	-456.34%
ANGO	250.7M	324.0M	16.79%	-29.66%	-1.3	0.77	-3.19%	-337.41%
APYX	43.7M	52.3M	1.60%	-56.21%	-2.33	0.83	17.61%	19.28%
AEMD	3.9M	3.7M	-13.45%	142.62%	-0.32	1.03	5.77%	8.23%

Zimmer Biomet Holdings Inc News

Latest updates

Zimmer Biomet Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	10.6%	1,940	1,754	1,870	1,831	1,825	1,670	1,782	1,663	1,777	1,685	1,763	1,601	2,085	1,929	1,226	1,784	2,126	1,892	1,989	1,976	2,071
Costs and Expenses	6.7%	1,586	1,487	1,540	1,504	1,853	1,425	1,501	1,465	1,643	1,442	1,539	1,343	777	1,630	1,398	2,240	793	1,647	1,784	1,625	2,862
S&GA Expenses	7.0%	722	675	726	716	727	655	695	685	805	684	697	657	429	790	665	829	349	826	839	796	999
EBITDA Margin	23.1%	0.25*	0.20*	0.20*	0.19*	0.17*	0.17*	0.17*	0.16*	0.18*	0.22*	0.22*	0.19*	-	-	-	-	-	-	-	-	-
Interest Expenses	1.6%	-50.30	-51.10	-51.60	-48.20	-42.60	-42.30	-38.80	-41.10	-48.80	-52.60	-54.70	-52.30	-53.20	-54.00	-54.00	-50.90	-52.50	-56.80	-59.70	-58.00	-68.50
Income Taxes	-339.7%	-135	56.00	67.00	54.00	55.00	-16.60	46.00	28.00	-29.20	28.00	33.00	21.00	-97.20	10.00	-13.70	5.00	-44.50	-247	8.00	46.00	37.00
Earnings Before Taxes	29.8%	285	219	277	287	-74.80	178	200	101	-83.90	191	178	214	365	256	-221	-503	264	185	140	292	-865
EBT Margin	48.4%	0.14*	0.10*	0.09*	0.08*	0.06*	0.06*	0.06*	0.06*	0.07*	0.13*	0.14*	0.09*	-	-	-	-	-	-	-	-	-
Net Income	157.7%	419	163	210	233	-130	194	154	14.00	-84.00	146	142	198	334	243	-206	-508	321	431	134	246	-901
Net Income Margin	112.5%	0.14*	0.07*	0.07*	0.06*	0.03*	0.04*	0.03*	0.03*	0.06*	0.11*	0.12*	0.08*	-	-	-	-	-	-	-	-	-
Free Cashflow	107.5%	526	253	251	261	181	404	305	279	288	380	394	198	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.3%	21,497	21,217	21,294	21,244	21,066	21,333	21,453	21,618	23,456	24,009	24,223	24,027	24,418	24,026	23,648	25,513	24,639	24,315	24,206	24,289	24,127
Current Assets	5.4%	4,610	4,372	4,388	4,412	4,427	4,534	4,463	4,517	4,885	5,312	5,357	5,000	5,083	5,153	4,707	6,371	4,724	4,402	4,391	4,499	4,427
Cash Equivalents	42.3%	416	292	320	330	376	545	386	436	378	920	1,042	724	775	967	713	2,434	618	513	403	587	543
Inventory	2.7%	2,385	2,323	2,276	2,241	2,147	2,129	2,123	2,132	2,148	2,517	2,533	2,512	2,174	2,492	2,497	2,463	2,385	2,362	2,345	2,310	2,257
Net PPE	1.4%	2,060	2,032	1,975	1,906	1,873	1,802	1,797	1,826	1,837	2,008	2,005	2,022	1,864	2,043	2,057	2,066	2,077	2,055	2,036	2,014	2,015
Goodwill	1.2%	8,819	8,710	8,744	8,735	8,580	8,799	8,869	8,896	8,919	9,212	9,248	9,233	8,983	9,039	8,982	8,951	9,197	9,545	9,594	9,570	9,594
Liabilities	3.6%	9,009	8,699	8,916	9,086	9,039	9,082	9,328	9,596	10,790	11,294	11,640	11,577	12,218	12,147	12,004	13,630	12,246	12,230	12,544	12,750	12,851
Current Liabilities	37.9%	2,857	2,072	2,234	2,336	2,358	2,296	2,464	2,674	3,468	2,939	2,929	2,089	2,557	2,266	2,161	3,780	3,442	3,774	3,678	2,255	2,421
Long Term Debt	-5.1%	4,868	5,127	5,189	5,205	5,152	5,055	5,172	5,286	5,464	6,458	6,803	7,539	7,627	7,840	7,759	7,724	6,721	6,346	6,719	8,311	8,414
LT Debt, Current	153.5%	900	355	520	585	544	659	852	1,015	1,605	1,046	1,050	300	500	450	450	1,950	1,500	2,000	2,000	500	525
LT Debt, Non Current	-5.1%	4,868	5,127	5,189	5,205	5,152	5,055	5,172	5,286	5,464	6,458	6,803	7,539	7,627	7,840	7,759	7,724	6,721	6,346	6,719	8,311	8,414
Shareholder's Equity	-0.2%	12,481	12,511	12,379	12,158	12,020	12,251	12,125	12,021	12,666	12,714	12,583	12,450	12,199	11,878	11,644	11,883	12,393	12,086	11,662	11,539	11,276
Retained Earnings	3.7%	10,385	10,015	9,902	9,742	9,559	9,740	9,607	9,503	10,292	10,426	10,331	10,238	10,087	9,803	9,610	9,866	10,427	10,155	9,773	9,688	9,491
Additional Paid-In Capital	0.5%	9,846	9,801	9,766	9,692	9,504	9,464	9,419	9,386	9,315	9,295	9,249	9,199	9,122	9,073	9,014	8,984	8,920	8,867	8,777	8,748	8,686
Shares Outstanding	-0.1%	209	209	209	209	210	210	209	209	209	209	209	208	-	-	-	-	-	-	-	-	-
Minority Interest	6.9%	8.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	6.00	3.00	4.00	5.00	4.00	3.00	5.00	5.00
Float	-	-	-	30,367	-	-	-	22,003	-	-	-	33,533,707,317	-	-	-	24,675,479,718	-	-	-	24,106	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	74.3%	588	338	348	308	244	451	346	316	338	424	419	224	296	381	-52.80	451	227	578	301	284	380
Share Based Compensation	62.2%	25.00	16.00	34.00	25.00	27.00	27.00	28.00	23.00	15.00	19.00	22.00	20.00	12.00	24.00	22.00	17.00	16.00	22.00	20.00	20.00	20.00
Cashflow From Investing	-33.3%	-220	-165	-243	-149	-112	-85.20	-243	-81.10	-124	-112	-98.90	-108	-266	-91.40	-85.30	-121	-53.40	-163	-322	-105	-82.40
Cashflow From Financing	-28.3%	-251	-196	-109	-206	-313	-193	-146	-122	-655	-426	-28.30	-195	-284	-42.60	-1,585	1,493	-180	-298	-163	-135	-275
Dividend Payments	0.2%	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	49.00	49.00	49.00	49.00	49.00
Buy Backs	-	410	-	14.00	268	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

ZBH Income Statement

2023-12-31

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Sales	$ 7,394.2	$ 6,939.9	$ 6,827.3
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization	$ 2,083.8	$ 2,019.5	$ 1,960.4
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization	$ 561.5	$ 526.8	$ 529.5
Research and development	458.7	406.0	435.8
Selling, general and administrative	2,838.9	2,761.7	2,843.4
Goodwill and intangible asset impairment		292.8	16.3
Restructuring and other cost reduction initiatives	151.9	191.6	125.7
Quality remediation		33.8	52.8
Acquisition, integration, divestiture and related	21.7	11.4	3.1
Operating expenses	6,116.5	6,243.6	5,967.0
Operating Profit	1,277.7	696.3	860.3
Other (expense) income, net	(9.3)	(128.0)	12.2
Interest expense, net	(201.2)	(164.8)	(208.4)
Loss on early extinguishment of debt			(165.1)
Earnings from continuing operations before income taxes	1,067.3	403.5	499.0
Provision for income taxes from continuing operations	42.2	112.3	53.5
Net Earnings from Continuing Operations	1,025.1	291.2	445.5
Less: Net earnings attributable to noncontrolling interest	1.1	1.0	0.5
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc.	1,024.0	290.2	445.0
Loss from Discontinued Operations, Net of Tax		(58.8)	(43.4)
Net Earnings of Zimmer Biomet Holdings, Inc.	$ 1,024.0	$ 231.4	$ 401.6
Basic Earnings Per Common Share
Earnings from Continuing Operations	$ 4.91	$ 1.38	$ 2.14
Loss from Discontinued Operations		(0.28)	(0.21)
Basic Earnings Per Common Share	4.91	1.1	1.93
Diluted Earnings Per Common Share
Earnings from Continuing Operations	4.88	1.38	2.12
Loss from Discontinued Operations		(0.28)	(0.21)
Diluted Earnings Per Common Share	$ 4.88	$ 1.1	$ 1.91
Weighted Average Common Shares Outstanding
Basic	208.7	209.6	208.6
Diluted	209.7	210.3	210.4

ZBH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 415.8	$ 375.7
Accounts receivable, less allowance for credit losses	1,442.4	1,381.5
Inventories	2,385.2	2,147.2
Prepaid expenses and other current assets	366.1	522.9
Total Current Assets	4,609.5	4,427.3
Property, plant and equipment, net	2,060.4	1,872.5
Goodwill	8,818.5	8,580.2
Intangible assets, net	4,856.4	5,063.8
Other assets	1,152.1	1,122.2
Total Assets	21,496.9	21,066.0
Current Liabilities:
Accounts payable	410.6	354.1
Income taxes payable	61.2	38.5
Other current liabilities	1,485.7	1,421.3
Current portion of long-term debt	900.0	544.3
Total Current Liabilities	2,857.4	2,358.2
Deferred income taxes, net	357.6	474.8
Long-term income tax payable	273.7	421.2
Other long-term liabilities	652.1	632.6
Long-term debt	4,867.9	5,152.2
Total Liabilities	9,008.7	9,039.0
Commitments and Contingencies (Note 21)
Stockholders' Equity:
Common stock, $0.01 par value, one billion shares authorized, 316.2 million (313.8 million in 2022) issued	3.2	3.1
Paid-in capital	9,846.1	9,504.4
Retained earnings	10,384.5	9,559.3
Accumulated other comprehensive loss	(191.0)	(179.3)
Treasury stock, 110.6 million shares (104.8 million shares in 2022)	(7,562.3)	(6,867.2)
Total Zimmer Biomet Holdings, Inc. stockholders' equity	12,480.5	12,020.3
Noncontrolling interest	7.7	6.7
Total Stockholders' Equity	12,488.1	12,027.0
Total Liabilities and Stockholders' Equity	$ 21,496.9	$ 21,066.0

About Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

CEO	Mr. Ivan Tornos
WEBSITE	zimmerbiomet.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	18000

Zimmer Biomet Holdings Inc Frequently Asked Questions

What is the ticker symbol for Zimmer Biomet Holdings Inc? What does ZBH stand for in stocks?

ZBH is the stock ticker symbol of Zimmer Biomet Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zimmer Biomet Holdings Inc (ZBH)?

As of Mon Apr 22 2024, market cap of Zimmer Biomet Holdings Inc is 24.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZBH stock?

You can check ZBH's fair value in chart for subscribers.

What is the fair value of ZBH stock?

You can check ZBH's fair value in chart for subscribers. The fair value of Zimmer Biomet Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zimmer Biomet Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZBH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zimmer Biomet Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ZBH is over valued or under valued. Whether Zimmer Biomet Holdings Inc is cheap or expensive depends on the assumptions which impact Zimmer Biomet Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZBH.

What is Zimmer Biomet Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, ZBH's PE ratio (Price to Earnings) is 24.19 and Price to Sales (PS) ratio is 3.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZBH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zimmer Biomet Holdings Inc's stock?

In the past 10 years, Zimmer Biomet Holdings Inc has provided 0.028 (multiply by 100 for percentage) rate of return.